SCHEMBL20604353

SCHEMBL20604353

COCOC(c1cccc(Cl)c1Cl)C(C)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
NFKB1 P19838 2/20 0.45
CYP3A4 P08684 1/20 0.45
PNMT P11086 1/20 0.45
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
GLA P06280 1/20 0.44
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ADRB2 P07550 2/20 0.36
ADRB1 P08588 2/20 0.36
KCNH2 Q12809 1/20 0.35
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
DRD2 P14416 2/20 0.34
DRD3 P35462 2/20 0.34
CYP2C19 P33261 1/20 0.33
AOC3 Q16853 1/20 0.33
ERCC5 P28715 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20604420 1.00 CYP1A2 (0.45) CYP1A2CYP2D6NFKB1CYP3A4PNMT
SCHEMBL20604351 1.00 CYP1A2 (0.45) CYP1A2CYP2D6NFKB1CYP3A4PNMT
SCHEMBL248196 0.88 ADRB2 (0.44) CYP1A2CYP2D6NFKB1CYP3A4ALDH1A1
SCHEMBL10323549 0.88 ADRB2 (0.44) CYP1A2CYP2D6NFKB1CYP3A4ALDH1A1
SCHEMBL27900787 0.88 ADRB2 (0.44) CYP1A2CYP2D6NFKB1CYP3A4ALDH1A1
SCHEMBL20604519 0.88 ADRB2 (0.44) CYP1A2CYP2D6NFKB1CYP3A4ALDH1A1
SCHEMBL10323379 0.88 ADRB2 (0.44) CYP1A2CYP2D6NFKB1CYP3A4ALDH1A1
SCHEMBL20604434 0.88 ADRB2 (0.44) CYP1A2CYP2D6NFKB1CYP3A4ALDH1A1
SCHEMBL10323550 0.88 ADRB2 (0.44) CYP1A2CYP2D6NFKB1CYP3A4ALDH1A1
SCHEMBL20604536 0.83 TSHR (0.33) CYP1A2CYP2D6NFKB1CYP3A4PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
EP-3423433-A1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES Bio-Pharm Solutions Co., Ltd. (KR) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses STS, SULT2A1, SULT1A1 CYP1A2 911/4885CYP2D6 871/4885NFKB1 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.